All In Biotech

Drug Trial Radar · NCT04344158

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 648 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

648

Planned (sponsor's estimate)

Start

Aug 11, 2020

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Apr 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC)

Interventions

  • AK105 InjectionDrug

    AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.

  • Anlotinib Hydrochloride CapsulesDrug

    Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

  • Sorafenib Tosylate TabletsDrug

    Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 96 weeks

Locations

81 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Beijing Ditan Hospital.Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing YouAn Hospital.Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Chinese Pla General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital.Capital Medical University

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • The first hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Second Nanning People's Hospital

    Nanning, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • The Second Affiliated Hospital of Hainan Medical Universit

    Haikou, Hainan, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • First Hospital Of Qinhuangdao

    Qinhuangdao, Hebie, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Heibei, China

  • Affiliated Tumor Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Nanyang First People's Hospita

    Nanyang, Henan, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

  • Xinxiang central hospital

    Xinxiang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.